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Commensal microbiota are well known to play an important role in
antiviral immunity by providing immune inductive signals; however,
the consequence of dysbiosis on antiviral immunity remains unclear.
We demonstrate that dysbiosis caused by oral antibiotic treatment
directly impairs antiviral immunity following viral infection of the
vaginal mucosa. Antibiotic-treatedmice succumbed tomucosal herpes
simplex virus type 2 infection more rapidly than water-fed mice, and
also showed delayed viral clearance at the site of infection. However,
innate immune responses, including type I IFN and proinflammatory
cytokine production at infection sites, as well as induction of virus-
specific CD4 and CD8 T-cell responses in draining lymph nodes, were
not impaired in antibiotic-treated mice. By screening the factors con-
trolling antiviral immunity, we found that IL-33, an alarmin released
in response to tissue damage, was secreted from vaginal epithelium
after the depletion of commensal microbiota. This cytokine sup-
presses local antiviral immunity by blocking the migration of effector
T cells to the vaginal tissue, thereby inhibiting the production of IFN-γ,
a critical cytokine for antiviral defense, at local infection sites. These
findings provide insight into the mechanisms of homeostasis main-
tained by commensal bacteria, and reveal a deleterious consequence
of dysbiosis in antiviral immune defense.
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Commensal microbiota perform various immunologic func-tions in mammals, including controlling the development of
lymphoid tissue, immune cell homeostasis, and the resistance to
invasive pathogens (1, 2). In particular, the role of commensal
microbiota in the regulation of antiviral immunity has been widely
studied. For example, commensal microbiota have been shown to
provide immune inductive signals for antiviral protection (3, 4).
Commensal microbiota supply signals for inflammasome activation
(3), and calibrate IFN responsiveness by providing tonic signals (4).
On the other hand, commensal microbiota are known to suppress
antiviral immunity by promoting viral entry and replication (5–7).
However, how commensal bacteria influence the effector arm of
antiviral immunity has not been studied.
Belkaid and colleagues recently reported the critical role of
commensal bacteria residing in barrier surfaces, such as skin for
local immunity against invasive pathogens (8). According to this
study, local resident commensals, rather than gut commensal
microbiota, provide signals supporting a microenvironment con-
ducive to protective immunity. The female genital tract, com-
posed of distinct upper and lower parts, is one such barrier
surface. The lower genital tract, the vaginal mucosa in particular,
is both the site of pathogen entry and the first line of defense
against pathogens. As with other barrier surfaces, commensal
microbiota, largely of the Lactobacillus species, shape the mi-
croenvironment of the vaginal tract. Lactobacilli produce hy-
drogen peroxide to prevent the outgrowth of harmful bacteria,
and maintain the acidic pH of the vaginal mucosa through lactic
acid production, which provides resistance against pathogens (9).
Imbalances in the vaginal flora, called dysbiosis, result in out-
growth of pathogenic bacteria; however, the consequence of
dysbiosis on genital antiviral immunity remains to be elucidated.
Genital herpes is a frequently relapsing, chronic viral disease.
It is not only one of the most common sexually transmitted viral
infections, but also a significant risk factor for other sexually
transmitted infections, such as HIV-1. Although several studies
in humans have described the association between bacterial
vaginosis and genital herpes simplex virus (HSV) infection (10,
11), the mechanisms through which dysbiosis modulates antiviral
immunity to HSV infection remain unclear.
To this end, we investigated the mechanisms by which com-
mensal bacteria elicit immune protection against HSV-2 infection
of the vaginal mucosa. We demonstrate that dysbiosis within the
vaginal microbiota leads to a dramatic increase in IL-33, which in
turn blocks the ability of effector T cells to migrate into the vaginal
tissue and secrete the antiviral cytokine IFN-γ, thereby rendering
the host susceptible to lethal infection by HSV-2.
Results
Defective Immune Protection Against Mucosal HSV-2 Infection in
Antibiotic-Treated Mice. Although there have been several studies
investigating the role of commensal bacteria in antiviral immunity,
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results vary depending on type of virus and route of exposure. For
example, commensal microbiota provide immune inductive signals
for antiviral immunity against mucosal influenza virus or systemic
lymphocytic choriomeningitis virus (LCMV) infections, whereas
commensal microbiota promote viral infection by murine leukemia
virus or poliovirus (3, 4, 6, 7). To determine the importance of
commensal bacteria in defense against mucosal infection by HSV-2,
we examined the outcome of intravaginal infection with 104 pfu of
WT HSV-2 after administration of a combination of five oral
antibiotics for 4 wk. All mice treated with antibiotics died within
11 d of viral infection, but some of the animals in the control
treatment group survived HSV-2 infection (Fig. 1A). Moreover,
antibiotic-treated mice exhibited more severe pathology than
control mice (Fig. 1B). We observed no difference in viral titers
from the vaginal secretion or vaginal tissue at early points after
infection; however, viral titers in the vagina remained significantly
elevated in antibiotic-treated mice at later time points (Fig. 1C). It
has been reported that administration of a Toll-like receptor ag-
onist mimicking the effect of commensal bacteria can restore
immunity in antibiotic-treated mice (3, 4, 12). Thus, we inoculated
mice locally (intravaginal) or distally (intrarectal or oral) with LPS
before mucosal HSV-2 infection. Unlike previous studies, neither
local nor distal LPS treatment enhanced the survival of antibiotic-
treated mice following HSV-2 infection (SI Appendix, Fig. S1A).
Taking these data together, we find that depletion of commensal
bacteria results in a severe defect in antiviral protection following
mucosal HSV-2 infection, and administration of LPS to mimic
commensal bacteria cannot recover protective immunity following
mucosal HSV-2 infection in antibiotic-treated mice.
Antibiotic Treatment Induces an Imbalance in Microbial Composition
of the Vaginal Mucosa. In vaginal ecosystems, a low diversity of
bacterial communities (dominated by Lactobacillus species)
seems to represent a healthy vaginal flora (13, 14). In contrast,
low diversity of the gut microbiota has been considered as a
causative factor for inflammatory bowel disease (15). To assess
the effects of antibiotic treatment on bacterial load and com-
position, stool and vaginal washes were collected from control
and antibiotic-treated mice. Microbiological analyses indicate
that antibiotic treatment results in a significant decrease in
bacterial density, predominantly diminishing Gram-positive
bacteria, in both the intestinal lumen and vaginal mucosa (Fig.
2A). In addition, the amount of 16S rDNA present in the stool
and vagina was significantly decreased in antibiotic-treated mice,
consistent with a reduced bacterial load (Fig. 2B). By using 16S
ribosomal DNA sequencing, we identified the change in com-
position of commensal microbiota inhabiting the vaginal mucosa
after 4 wk of antibiotic treatment. Consistent with our microbi-
ological analysis, a portion of Gram-positive bacteria (e.g., Fir-
micutes) was decreased, whereas Gram-negative Proteobacteria
was increased after antibiotic treatment (Fig. 2C). Assessment of
vaginal microbiota revealed that bacterial composition diversi-
fied after treatment, and these compositional changes started
as early as week 1 after antibiotic treatment (SI Appendix, Fig.
S2A). Furthermore, in antibiotic-treated mice these bacteria
formed a cluster that was distinct from that of controls (SI Ap-
pendix, Fig. S2B). Collectively, these data show that although the
amount of bacterial colonization was diminished, various species
of bacteria different from that of control mice colonized in
vaginal mucosa after antibiotic treatment.
Next, to investigate which bacterial classes are responsible for
immune protection against mucosal HSV-2 infection, we treated
mice with a single type of antibiotic. Treatment with any anti-
biotic alone did not induce the same level of severe mortality or
morbidity as treatment with all of the antibiotics combined (SI
Appendix, Fig. S1 B and C). These results indicate that not just
one class of commensal bacteria takes responsibility for immune
protection against mucosal HSV-2 infection. Instead, it is the
imbalance of vaginal commensal bacteria that renders antibiotic-
treated mice susceptible to mucosal HSV-2 infection, because
only treatment with five oral antibiotics, not any single type of
antibiotic, induced severe mortality and morbidity after HSV-2
infection.
Innate Immunity to Mucosal HSV-2 Infection Is Not Affected by
Antibiotic Treatment. To investigate how commensal microbiota
support immune protection against HSV-2 infection in the vag-
inal mucosa, we first explored the effect of commensal bacteria
on the innate immune response. Innate immunity plays a pivotal
role in limiting viral replication and initiating adaptive immunity
in response to primary viral infection (16, 17). Following vaginal
mucosal HSV-2 infection, production of proinflammatory cyto-
kines, such as IL-6, TNF-α, and IL-12p40, was not impaired in
antibiotic-treated mice (Fig. 3A). However, consistent with pre-
vious studies (3, 8), antibiotic treatment reduced the production
of IL-1 family cytokines, such as IL-1α, IL-1β, and IL-18 (Fig.
3B). Notably, pro–IL-1β production by the vaginal mucosa was
reduced in antibiotic-treated mice relative to control-treated
mice, both at steady state and after viral infection (SI Appendix,
Fig. S3A). However, treatment with IL-1β could not restore
protective immunity against mucosal HSV-2 infection in antibi-
otic-treated mice (SI Appendix, Fig. S3 B and C).
Type I IFNs are centrally involved in innate antiviral defense
through up-regulation of numerous IFN stimulatory genes that
antagonize viral replication and activate adaptive immunity (18).
Type III IFNs, such as IFN-λ, are also known to exert type I IFN-
like antiviral activities, especially on mucosal epithelia (19, 20).
Previously, commensal bacteria have been shown to contribute
to IFN responses against systemic LCMV and respiratory influenza
virus infection (4). However, we found that type I IFNs, including
IFN-α and IFN-β, and type III IFN (IFN-λ) production was not
impaired, rather slightly increased, following HSV-2 infection of
the vaginal mucosa in antibiotic-treated mice (Fig. 3C).
To test whether innate effector cells trafficked normally to
the site of infection following administration of antibiotics, we
examined the proportion and number of effector immune cell
Fig. 1. Commensal microbiota control immune protection against mucosal
HSV-2 infection. C57BL/6 mice were given ampicillin, vancomycin, neomycin
sulfate, gentamicin, and metronidazole (ABX) in drinking water or were
given DW as a control for 4 wk before intravaginal WT HSV-2 infection
(104 pfu per mouse). Survival (A) and disease scores (B) were assessed for
1 mo postchallenge (n = 5 mice). Similar results were obtained from five in-
dependent experiments. (C, Left) At the indicated days postinfection, HSV-2
viral titers from vaginal washes were measured on Vero cells. (Right) Genome
copy number of HSV-2 gB DNA isolated from vaginal tissues was determined by
PCR. Data are representative of two independent experiments (n = 3–5mice per
group). *P < 0.05; **P < 0.01; ns, not significant. Error bars: SEM.



























subsets, including dendritic cells, plasmacytoid dendritic cells,
inflammatory monocytes, neutrophils, and eosinophils in the
vaginal tissue early after infection (Fig. 3D). Our data demon-
strate that both the proportion and number of eosinophils were
markedly increased regardless of infection, whereas other innate
immune cells migrated similarly to the site of infection in anti-
biotic-treated and control-treated mice. Collectively, these re-
sults suggest that the innate immune response to mucosal HSV-2
infection is not impaired following treatment with antibiotics.
Instead, antibiotic treatment induces an increase in tissue eo-
sinophils, even in the absence of viral infection.
Impaired Recruitment of Effector T Cells to the Site of Infection
Despite Normal T-Cell Priming. Next, we evaluated the possibility
that commensal bacteria contribute to adaptive immunity against
mucosal HSV-2 infection. In HSV-2 infection, both CD4 T and
CD8 T cells and the IFN-γ produced by these cells are essential
for defense (21). However, no significant changes in the fre-
quency of IFN-γ–producing CD4 or CD8 T cells were found in
either draining lymph nodes or vaginal tissues after antibiotic
treatment (SI Appendix, Fig. S4). Moreover, T-cell priming in
draining lymph nodes after vaginal mucosal HSV-2 infection was
not impaired in antibiotic-treated mice (Fig. 4A).
Despite the lack of a defect in T-cell priming, it is possible that
immune defense might be impaired at the vaginal mucosa be-
cause of defective migration of effector T cells from the site of
immune induction to the site of viral replication (22, 23). To see
whether activated T cells were properly recruited to the infection
site, we measured the frequency of CD4 and CD8 T cells in
vaginal tissue and found that the frequency of these cells and the
number of activated T cells, defined as CD44+CD62L−, in vag-
inal tissues were markedly reduced in antibiotic-treated mice
after infection (Fig. 4B). Moreover, the level of IFN-γ, a crucial
cytokine for local protection against mucosal HSV-2 infection,
was markedly reduced in vaginal washes on day 5 after HSV-2
infection of antibiotic-treated mice. Furthermore, CXCL9, which
induces recruitment of T cells to the infection site in response to
IFN-γ, was decreased as well. In contrast, the level of CXCL10,
which plays a similar role to CXCL9, was comparable between
the two groups, likely because CXCL10 is also induced in re-
sponse to other types of IFNs (24) (Fig. 4C).
In addition, we investigated whether a shorter duration of
antibiotic treatment could affect immune responses against mu-
cosal HSV-2 infection because the amount and the composi-
tional changes in vaginal microbiota start as early as 1 wk after
treatment. Interestingly, a 2-wk treatment with antibiotics also
resulted in an impairment in immune protection, leading to poor
survival and severe pathology (SI Appendix, Fig. S5A). Notably,
we also observed higher viral titers in the vagina of antibiotic-
treated mice than control mice at late time points, whereas viral
titers at early times did not differ (SI Appendix, Fig. S5B). Similar
to previous results, 2 wk of antibiotic treatment resulted in a re-
duced proportion and number of CD4 and CD8 T cells in vaginal
tissue after viral infection (SI Appendix, Fig. S5C). Moreover, cy-
tokines and chemokines (such as IFN-γ and CXCL9) in vaginal
fluids of these mice were markedly reduced on day 5 after HSV-2
infection (SI Appendix, Fig. S5D). Together, these results indicate
that defective migration of effector T cells in antibiotic-treated
mice induces diminished production of IFN-γ at the site of in-
fection in the same time frame as the amount and composition of
vaginal microbiota change.
Antibiotic Treatment Induces the Secretion of IL-33, Which Recruits
Type 2 Innate Lymphoid Cells and, Subsequently, Eosinophils to the
Vaginal Mucosa.To investigate what influences the defects in local
immune defense found under conditions that deplete commen-
sal microbiota, we performed a proteomic analysis to identify
changes in the abundance of specific vaginal wash proteins in
Fig. 2. Decreased bacterial colonization, but increased bacterial diversity,
after antibiotic treatment. C57BL/6 mice were administered antibiotics in
drinking water for 4 wk. (A) Bacterial loads in stools and vaginal washes
pooled from five mice were measured. Data are a compilation of three ex-
periments. Error bars: SEM. (B) Stool and vaginal wash pellets pooled from
six mice were collected before (week 0) or during (weeks 1–4) antibiotic
treatment. Relative gene copies of 16S rDNA isolated from stool and vaginal
wash pellets were quantified by qPCR. Error bars represent SEM of technical
duplicates. Similar results were obtained from two independent experi-
ments. (C) Double pie charts demonstrating the microbial communities re-
siding in vaginal washes collected from DW or ABX mice (n = 10 mice pooled
per group). Inner pie: composition of phyla; Outer pie: composition of
genera. Similar results were obtained from two independent experiments.
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antibiotic-treated mice relative to untreated controls. Of 184
proteins identified, 26 were significantly increased (≥threefold)
in vaginal wash fluid from antibiotic-treated mice relative to un-
treated controls (SI Appendix, Tables S1–S3). The level of pro-
teins associated with tissue damage (serum albumin, S100-A8,
S100-A9) and acute-phase proteins representing inflammation
(ceruloplasmin, ferritin, α-1-antitrypsin) was increased in vaginal
wash fluid. Consistently, the level of albumin was also found to be
increased in vaginal wash fluid after antibiotic treatment when
measured by ELISA (Fig. 5A). On the basis of these results, we
hypothesized that factors driven by inflammatory damage of
vaginal epithelial cells during antibiotic treatment modulate
local immunity.
Based on the fact that IL-33 is one of well-known damage-
associated molecules, we tried to detect IL-33 in vaginal washes
of antibiotic-treated mice. Using nanoflow liquid chromatography
electrospray-tandem mass spectrometry analysis, we detected a
dramatic increase in IL-33 at 1 wk postantibiotic treatment (SI
Appendix, Fig. S6). Similarly, the level of IL-33 measured by ELISA
was also increased in the vaginal wash fluid over the course of
antibiotic treatment (Fig. 5B). Meanwhile, other cytokines related
to innate (IL-1α, TNF-α, IL-6) and adaptive (IFN-γ, IL-4) immu-
nity, as well as epithelial-derived cytokines (IL-25, TSLP), did not
increase during antibiotic treatment (SI Appendix, Fig. S7).
IL-33 is well known for its involvement in Th2-related immune
responses. The receptor for IL-33 consists of ST2 (also known as
IL-33R), which is highly expressed on type 2 innate lymphoid
cells (ILC2), and IL-1R accessory protein (IL-1RAcP) (25).
Upon activation by IL-33, ILC2 release type 2 cytokines, such as
IL-5 and IL-13, and this IL-33–mediated ILC2 activation promotes
Fig. 4. IFN-γ production at the local infection site is impaired after mucosal
HSV-2 infection of antibiotic-treated mice. C57BL/6 mice fed with antibiotics
(ABX) in drinking water or DW for 4 wk were infected intravaginally with
HSV-2. (A) At day 6 postinfection with 106 pfu of TK-HSV-2, IFN-γ produced
by CD4 or CD8 T cells isolated from draining lymph nodes after restimulation
with heat-inactivated HSV-2 or gB peptide for 72 h was measured using
ELISA (n = 3 mice). Data are representative of three independent experi-
ments. (B) At day 6 postinfection with 104 pfu of WT HSV-2, the recruitment
of CD4 and CD8 T cells to vaginal tissues was assessed using flow cytometry.
Plots were gated on DAPI−CD45.2+ cells and numbers indicate the percent-
age of gated cells. The numbers of activated (identified as CD44+CD62L−)
CD4 T and CD8 T cells were assessed (mock, n = 4 mice; HSV-2, n = 7 mice).
Data are a compilation of three experiments. (C) Levels of IFN-γ and the IFN-
inducible chemokines CXCL9 and CXCL10 were measured in vaginal washes
at day 5 postinfection with 104 pfu of WT HSV-2 using ELISA (DW, n = 5 mice;
ABX, n = 6 mice). Data are representative of three independent experiments.
*P < 0.05; **P < 0.01; ns, not significant. Error bars: SEM.
Fig. 3. Innate immune response against mucosal HSV-2 infection is not
impaired in antibiotic-treated mice. C57BL/6 mice fed with antibiotics (ABX)
in drinking water or DW for 4 wk were infected intravaginally with 104 pfu
of WT HSV-2. (A–C) At the indicated days postinfection, levels of (A) proin-
flammatory cytokines including IL-12p40, IL-6, and TNF-α; (B) IL-1 family cyto-
kines including IL-1α, IL-1β, and IL-18; and (C) IFNs, including IFN-α, IFN-β, and
IFN-λ, were measured in vaginal washes using ELISA (DW, n = 5mice; ABX, n = 6
mice). Similar results were obtained from two independent experiments. (D) At
48 h, frequency (Upper) and number per mouse (Lower) of innate immune cells
in vaginal tissues were assessed using flow cytometric analysis (n = 3 mice).
Plasmacytoid DCs (pDCs) were defined as Ly6C+BST2+CD11c+CD11b− cells,
dendritic cells (DCs) as MHCII+CD11c+ cells, Ly6Chi monocytes as Ly6ChighCD11b+
cells, neutrophils as Ly6G+CD11b+ cells, and eosinophils as Siglec-F+CD11b+ cells.
Data are representative of three independent experiments. *P < 0.05; **P <
0.01. Error bars: SEM.



























Fig. 5. IL-33 secretion, which promotes Th2-related immune responses, is induced in vaginal mucosa after antibiotic treatment. (A–E) C57BL/6 mice were
administered antibiotics (ABX) in drinking water or DW for 4 wk. (A) Albumin level was measured by ELISA from vaginal washes during antibiotic treatment
(DW, n = 5 mice; ABX, n = 6 mice). (B) Level of IL-33 was measured in vaginal washes collected during the course of antibiotic treatment by ELISA (DW, n = 5
mice; ABX, n = 6 mice). (C, Left) After 4 wk of antibiotic treatment, the frequency of lineage (CD3e, B220, CD11b, CD11c, NK1.1, and FceRI)−Sca-1+C-kit+ST2+IL-
7R+ innate lymphoid cells in vaginal tissues was analyzed by flow cytometry. Numbers indicate percentage of gated cells. (Right) The number of innate
lymphoid cells in vaginal tissues after 1 wk and 4 wk of antibiotic treatment was assessed (DW, n = 5 mice pooled; ABX, n = 6 mice pooled). (D) Level of IL-5
was measured in vaginal washes collected during the course of antibiotic treatment by ELISA (DW, n = 5 mice; ABX, n = 6 mice). (E) Frequency and number of
M2 macrophages in vaginal tissues were assessed using flow cytometric analysis (DW, n = 4 mice; ABX, n = 5 mice). M2 macrophages were defined as CD206+
F4/80+CD11b+ cells. (F and G) C57BL/6 mice were injected intraperitoneally with recombinant IL-33 or PBS daily for 8 d. (F) Iliac lymph nodes and vaginal tissues
were collected, and the number of immune cells analyzed by flow cytometry was graphed (n = 4 mice). Eosinophils were defined as Siglec-F+CD11b+ cells,
monocytes as Ly6ChighCD11b+ cells, and neutrophils as Ly6G+CD11b+ cells. (G) Six days after final injection, IL-4 production by CD3e-CD4-CD8α- cells from iliac
lymph nodes was measured by intracellular cytokine staining after stimulation with PMA and ionomycin (n = 3 mice). Data are representative of two to three
independent experiments *P < 0.05; **P < 0.01; ***P < 0.001. Error bars: SEM.
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recruitment of innate cells involved in type 2 responses, including
eosinophils (26, 27). To reveal the mechanism through which IL-33
acts and identify the cells affected by this cytokine in our study, we
determined which cells expressed ST2 in vaginal tissues before
HSV-2 infection. We discovered that ILC2, which express Sca-1,
C-kit, ST2, and IL-7R, but not hematopoietic lineage markers, are
Fig. 6. IL-33 suppresses immune protection against mucosal HSV-2 infection. (A–E) C57BL/6 mice were injected intraperitoneally with recombinant IL-33 (2 μg per
mouse) or PBS daily for 8 d. Immediately after the final injection, mice were infected intravaginally with 104 pfu of WT HSV-2. (A) Survival and disease scores were
monitored, and (B) vaginal washes were collected on the indicated days postinfection to measure IFN-γ by ELISA (PBS, n = 5 mice; rIL-33, n = 6 mice). (C) At day 6
postinfection, the recruitment of CD4 and CD8 T cells to vaginal tissues was assessed by flow cytometry. Plots were gated onDAPI−CD45.2+ cells and numbers indicate the
percentage of gated cells (n = 3 mice per group). (D) Vaginal washes were collected at 5 d postinfection to measure CXCL9 and CXCL10 by ELISA (PBS, n = 5 mice; rIL-33,
n = 6 mice). (E) At day 6 postinfection, IFN-γ produced by CD4 or CD8 T cells isolated from draining lymph nodes after restimulation with heat-inactivated HSV-2 or gB
peptide for 72 h was measured by ELISA (n = 3 mice). (F) IL-33+/−or IL-33−/−mice were injected intraperitoneally with recombinant IL-33 or PBS daily for 8 d. Immediately
after the final injection of IL-33, mice were infected intravaginally with 104 pfu WT HSV-2. Survival and disease scores were monitored (n = 5–7 mice per group). (G) IL-
33+/−or IL-33−/−mice fed with antibiotics (ABX) in drinking water or DW for 4 wkwere infected intravaginally with 102 pfu (Left) or 104 pfu (Right) of WT HSV-2. Survival
was monitored (n = 4–5 mice per group). Data are representative of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars: SEM.



























present in the vaginal mucosa of antibiotic-treated mice (Fig. 5C).
In addition, the level of IL-5 was also increased in the vaginal wash
fluid over the course of antibiotic treatment (Fig. 5D). In the
context of tissue damage after antibiotic treatment, we tried to
detect alternatively activated macrophages (AAMs, M2 macro-
phage), which regulate the tissue repair response, in the vaginal
tissue. After antibiotic treatment, however, the proportion and
number of AAMs did not increase in the vaginal tissue (Fig. 5E).
Combined with the data showing that the proportion and
number of eosinophils are markedly increased in the vaginal
tissue after antibiotic treatment (Fig. 3D), we concluded that
damage-associated production of IL-33 in antibiotic-treated
mice facilitates the recruitment of ILC2 into the vaginal mu-
cosa, which leads to the production of IL-5 and accumulation of
eosinophils in vaginal tissues.
IL-33 Contributes to Impaired Antiviral Immunity to Mucosal HSV-2
Infection. Next, to corroborate a role for IL-33 in modulating
local immune defense against HSV-2, we injected mice with
recombinant IL-33 (rIL-33) every day for 8 d before viral in-
fection. Mice injected with rIL-33 exhibited eosinophil infiltra-
tion into the iliac lymph nodes and vaginal mucosa (Fig. 5F and
SI Appendix, Fig. S8). Moreover, IL-4 was produced from non-B
and non-T cells in the iliac lymph nodes of these mice, even at
steady state (Fig. 5G). After HSV-2 infection, mice injected with
rIL-33 died much faster and exhibited more severe pathology
than control mice (Fig. 6A). These mice were unable to produce
IFN-γ in vaginal mucosa at 5 d postinfection (Fig. 6B), as shown
in antibiotic-treated mice. Furthermore, in mice injected with
rIL-33, the recruitment of effector T cells to the site of infection
was defective (Fig. 6C), although T-cell priming in the draining
lymph nodes was not impaired (Fig. 6E). In addition, CXCL9
and CXCL10 production from vaginal mucosa was reduced in
these mice at 5 d postinfection (Fig. 6D). Notably, mice treated
locally with rIL-33 also showed impaired survival and more se-
vere pathology than control mice (SI Appendix, Fig. S9A), which
suggests that the local effect of IL-33 is sufficient to suppress
protective immunity against mucosal HSV-2 infection.
IL-33 is known to drive protective, antiviral cytotoxic T lym-
phocyte responses in cases of systemic LCMV infection (28).
However, IL-33–deficient mice exhibited a survival rate and
pathology score comparable to those of control mice in response
to vaginal mucosal HSV-2 infection (SI Appendix, Fig. S9B).
Moreover, CD4 and CD8 T-cell–derived IFN-γ production was
normal in the draining lymph nodes and vagina of IL-33–
deficient mice (SI Appendix, Fig. S9C). To elucidate the distinct
role of IL-33 during vaginal mucosal HSV-2 infection, we in-
jected rIL-33 into IL-33–deficient mice and then infected these
mice with WT HSV-2 intravaginally. Like IL-33 heterozygous
mice injected with rIL-33, IL-33–deficient mice injected with
rIL-33 were susceptible to mucosal HSV-2 infection (Fig. 6F).
Moreover, IL-33–deficient mice treated with antibiotics showed
comparable survival rates with untreated mice (distilled water,
DW) when infected with a low dose of HSV-2; however, these
mice could not overcome the defect in protection caused by
antibiotic treatment when infected with a high dose of HSV-2
(Fig. 6G). Taken together, these findings suggest that IL-33
could be a key factor in the suppression of antiviral immunity
following mucosal HSV-2 infection through the inhibition of
local IFN-γ production as a result of defective migration of effector
T cells to local infection sites.
Proteases, Such as Those Induced by Dysbiosis, Induce IL-33 Secretion
in the Vaginal Mucosa and Lead to Impaired Antiviral Immunity to
Mucosal HSV-2 Infection. Commensal microbiota confer host pro-
tection from damage by exogenous pathogens (29). Thus, we
hypothesized that IL-33, an alarmin released from dying cells,
may be induced by damage caused by pathogens grown out after
antibiotic treatment. By analyzing 16S ribosomal sequencing
data, we found that the relative abundance of Serratia and
Pseudomonas was increased in antibiotic-treated mice (Fig. 7A
and SI Appendix, Fig. S2C). Based on the evidence that some
species of Serratia and Pseudomonas are able to produce prote-
ases (30–32), especially cysteine protease (33–35), we investigated
whether IL-33 is secreted in vaginal mucosa after treatment with
papain, a cysteine protease. Although papain treatment mimics an
acute response and antibiotic treatment leads to a long-term effect
on vaginal commensals, we discovered that IL-33 levels in vaginal
mucosa increased after papain treatment and then gradually de-
creased (Fig. 7B). Moreover, pretreatment with active papain
resulted in poor survival and severe pathology following mucosal
HSV-2 infection (Fig. 7C). These findings suggest that protease-
producing pathogenic bacteria, which grow abundantly as a result
of oral antibiotic treatment, may induce IL-33 secretion in vaginal
mucosa, and in turn lead to impaired antiviral immunity against
mucosal HSV-2 infection.
Discussion
Our findings suggest a previously unknown effect of commensal
microbiota on the local tissue microenvironment during the ef-
fector phase of defense against viral infection. Antibiotic-mediated
depletion of commensal microbiota impaired antiviral immunity,
which resulted in severe morbidity and mortality and poor con-
trol of viral replication following mucosal HSV-2 infection.
Fig. 7. Proteases, such as those induced by dysbiosis, induce IL-33 secretion
into the vaginal mucosa, and lead to impaired antiviral immunity against mu-
cosal HSV-2 infection. (A) Bar plots indicate relative abundance of bacterial
species that predominate in ABX mice (n = 6 mice) over DW mice (n = 5 mice).
(B) IL-33 was measured by ELISA of vaginal washes collected after intravaginal
injection of the protease papain for 3 consecutive days (n = 11 mice). Data are
representative of two independent experiments. (C) C57BL/6 mice were in-
jected intravaginally with active papain or heat-inactivated (HI) papain for 3
consecutive days. At 4 d after final injection, mice were infected intravaginally
with 103 pfu of WT HSV-2. Survival and disease scores were monitored for 4 wk
postchallenge (n = 10–11 mice per group). Data are representative of two in-
dependent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars: SEM.
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Furthermore, not only did antibiotic treatment reduce com-
mensal microbiota, it also increased the antibiotic-resistant
microbiota, resulting in an imbalance in the microbial composi-
tion of the vaginal tract. The susceptibility of antibiotic-treated
mice was attributed to compromised effector T-cell responses
rather than defects in innate immunity. Specifically, we found
that IL-33 secreted from damaged epithelia recruited ILC2 and
subsequently eosinophils into vaginal tissue, which contributed to
suppression of antiviral immunity against mucosal HSV-2 in-
fection. Finally, protease activity induces increased levels of IL-
33 in the vaginal tract, suggesting that proteases produced by
some antibiotic-resistant bacterial species may exert similar ef-
fects in vivo. Taken together, these results indicate that dysbiosis-
induced IL-33 contributes to the impaired antiviral immunity
against mucosal HSV-2 infection.
The role of commensal microbiota in the regulation of anti-
viral immunity has been studied previously (3, 4). In these
studies, commensal microbiota provided immune inductive sig-
nals for inflammasome activation or calibration of IFN respon-
siveness. Therefore, depletion of commensal microbiota resulted
in defective immune responses against mucosal and systemic
virus infections. In contrast, our results suggest that dysbiosis
rather than reduction of commensal microbiota are more likely
to contribute to impairment of protective immunity against mu-
cosal HSV-2 infection. Recent human study also supports that
high diversity vaginal microbiome correlates with high suscepti-
bility to genital infections (14). Inoculation of Toll-like receptor
agonists to reconstitute the effects of commensal bacteria could
not restore immune responses in our study, but this treatment
completely restored antiviral immunity in other studies (3, 4). In
addition, treatment with single antibiotics was previously found
to reduce immune responses (3), whereas we found that treat-
ment with any antibiotic alone did not induce the same level of
mortality or morbidity as treatment with a combination of anti-
biotics. Collectively, these findings suggest that impaired pro-
tection against mucosal HSV-2 infection in antibiotic-treated
mice is not a consequence of a reduction in commensal bacteria
or depletion of a specific group of bacteria. Instead, the effect of
antibiotic-resistant microbiota predominated in the vaginal mi-
croenvironment renders antibiotic-treated mice susceptible to
mucosal HSV-2 infection.
IL-33 is one of several epithelial cell-derived cytokines (in-
cluding IL-25 and TSLP), and functions as an alarmin released in
response to tissue damage. Although epithelial barrier tissues
and endothelial cells are generally known to express IL-33 (36,
37), some immune cells, such as macrophages and dendritic cells,
can produce IL-33 under certain inflammatory conditions (38,
39). However, the level of IL-33 produced by hematopoietic cells
is much less than that from epithelial cells (39, 40), and tissue-
derived IL-33 is critical for induction of allergic inflammation
(41). IL-33 signals through the ST2/IL–1RAcP complex, mainly
expressed in ILC2, mast cells, basophils, eosinophils, Th2 cells,
NKT, and NK cells (25, 42, 43). Notably, ILC2, one of the initial
targets of IL-33 because of their constitutive expression of ST2,
mediates type-2 immunity through secretion of type 2 cytokines,
such as IL-5 and IL-13. These cytokines induce tissue eosino-
philia, goblet cell hyperplasia with increased mucus production,
and recruitment and activation of AAMs and Th2 cells, which
together induce and reinforce type 2 immunity (44). In our study,
antibiotic treatment markedly increased IL-33 secretion from
vaginal epithelia, which induced the recruitment of ILC2s into
vaginal tissue. In addition, the level of IL-5 was also increased in
parallel with IL-33, and eosinophils infiltrated into vaginal tissue
in antibiotic-treated mice. Although the exact mechanism through
which IL-33 impedes the migration of IFN-γ–producing T cells
remains to be determined, we assume that IL-33 acts locally on
ILC2 to induce the secretion of type 2 cytokines and subsequent
recruitment of eosinophils into vaginal tissue, thereby inhibiting
the secretion of IFN-γ from recruited T cells. This process would
result in a reduction of IFN-induced chemokines CXCL9 and
CXCL10 and, as a result, a reduction in further recruitment of
effector T cells.
In our study, exogenous IL-33 dramatically suppressed anti-
viral immunity against mucosal HSV-2 infection by blocking the
ability of IFN-γ–producing T cells to migrate into the vaginal tis-
sue. However, antibiotic-treated mice were still susceptible to
HSV-2 infection even in the absence of IL-33, when infected with
a lethal dose of HSV-2. In contrast, antibiotic-treated IL-33–
deficient mice survived comparable to water-fed control mice
when they were infected with a sublethal dose of HSV-2. Unlike
exogenous IL-33 treatment, antibiotic treatment could induce
various changes affecting host immune responses besides IL-33
secretion from vaginal epithelia. Although changes in antibi-
otic-treated mice, including diminished production of IL-1 family
cytokines, might contribute to impaired protective immune re-
sponses (3, 8), IL-33 was found to be sufficient to suppress antiviral
immunity against genital HSV-2 infection. However, in the absence
of IL-33 signals, antibiotic-mediated immunologic changes could
render these mice susceptible to HSV-2 infection, although this
suppression could be overcome by the host immune system at
lower viral titers. Thus, we concluded that IL-33 induced by anti-
biotic treatment might be a dominant modulator suppressing host
antiviral immunity against mucosal HSV-2 infection.
Although previous studies have shown that stimulatory signals
from commensal microbiota are crucial for defense against viral
infection (3, 4), our present study demonstrates that inhibitory
signals induced by the depletion of commensal microbiota also
affect antiviral immunity. Taken together, our findings provide a
unique insight into the role of commensal bacteria in maintain-
ing the integrity of surface barrier epithelial cells by preventing
pathogenic bacteria colonization, thereby supporting a micro-
environment conducive to antiviral defense. These results also
prompt clinically relevant questions regarding the use of oral
antibiotics and the potential for increased susceptibility to vari-
ous sexually transmitted viruses.
Materials and Methods
Mice. Female 6- to 8-wk-old C57BL/6 specific pathogen-free mice were pur-
chased from DBL Co. Ltd, Korea. IL-33−/− mice (45) were kindly provided by
the RIKEN Center for Developmental Biology. All mice were housed in a
specific pathogen-free facility of the Korea Advanced Institute of Science
and Technology (KAIST). All procedures involving animals were in accor-
dance with the guidelines and protocol (KA2013-55) for rodent experi-
mentation provided by the Institutional Animal Care and Use Committee
of KAIST.
Antibiotic Treatment. Mice were treated with ampicillin (500 mg/L; AG Sci-
entific), vancomycin (250mg/L; AG Scientific), neomycin sulfate (500mg/L; AG
Scientific), gentamicin (500 mg/L; AG scientific), and metronidazole (500 mg/L;
Sigma) in drinking water for 2 or 4 wk, as previously described (4). Antibiotic
treatment was started 2 or 4 wk before infection and continued for the du-
ration of the experiment. For some experiments, individual antibiotics (at the
indicated concentrations) were administered in drinking water.
Virus and Intravaginal Infection. The WT and TK- HSV-2 strains provided by A.
Iwasaki (Yale University, NewHaven, CT) were used for all experiments. HSV-2
was propagated and titrated using a plaque assay on Vero cells. For intra-
vaginal virus infection, mice were injected subcutaneously with medroxy-
progesterone acetate (Tokyo Chemical Industry) at 2 mg per mouse in 100 μL
at 5–7 d before infection, swabbed with calcium alginate, and inoculated
intravaginally with 102 to 104 pfu WT or 106 pfu TK- HSV-2 in 10 μL using a
blunt-ended micropipette tip, as previously described (46). Upon WT HSV-2
challenge, disease severity was scored as follows (47): 0, no sign; 1, slight
genital erythema and edema; 2, moderate genital inflammation; 3, purulent
genital lesions; 4, hind-limb paralysis; 5, premoribund. Because of humane
concerns, the animals were killed before reaching the moribund state.



























Vaginal Viral Titration and Measurement of Cytokines and Albumin. Vaginal
fluids were collected from 0 to 6 d after infection by pipetting PBS (50 μL) into
and out of the vagina 20 times. Viral titers were measured by titrating
vaginal fluids on Vero cells for 72 h in duplicate, as described previously (48).
Levels of IL-1β, IL-12p40, IL-6, IL-5 (BD Biosciences), IL-4, IFN-γ, TNF-α, IFN-α,
IFN-β, IL-33, IL-25, TSLP (eBioscience), IL-1α (BioLegend), IFN-λ, CXCL9,
CXCL10 (R&D Systems), IL-18 (MBL Co., Ltd) and albumin (Immunology
Consultants Laboratory) in vaginal fluids were measured using an ELISA kit
according to manufacturer’s instructions.
Detection of HSV-2 Glycoprotein B DNA by Quantitative PCR. After infection,
vaginal tissue was collected and total genomic DNA was extracted according
to the manufacturer’s instructions (Qiagen). HSV-2 was measured using
primers against glycoprotein B (gB) (forward: 5′-CACCGCTACTCCCAGTT-
TATG-3′; reverse: 5′-CGGTGGTCTCCATGTTGTT-3′) by quantitative PCR (qPCR;
Bio-Rad). DNA purified from WT HSV-2 was used as the standard to calculate
plaque-forming unit equivalents.
Treatment with Recombinant IL-33. rIL-33 was purchased from BioLegend. For
systemic treatment, mice were injected intraperitoneally with 2 μg of rIL-33
daily for 8 d before intravaginal virus infection, as previously described, with
modifications (28). For local treatment, mice were injected intravaginally with
4 μg of rIL-33 daily for 5 d before intravaginal virus infection after anes-
thesia with intraperitoneal ketamine (100 mg/kg) and xylazine (5.83 mg/kg)
injection (49).
CD4 and CD8 T-Cell Responses. HSV-specific T-cell responses were analyzed as
previously described (46). At day 6 postinfection, CD4 and CD8 T cells were
isolated from the draining lymph nodes of mice infected intravaginally with
106 pfu of TK- HSV-2 using anti-CD4– or anti-CD8–conjugated microbeads
(Miltenyi Biotech) according to the manufacturer’s instructions. Next, 1 × 105
CD4 and CD8 T cells were restimulated with various amounts of heat-
inactivated HSV-2 or HSV gB peptide (SSIEFARL) for 72 h at 37 °C. IFN-γ
production in supernatants was measured by ELISA.
Flow Cytometry. Single-cell suspensions were prepared from the iliac lymph
nodes and vagina according to previously described methods, with slight
modifications (48). Single cells were pretreated with anti-CD16/32 antibody
(2.4G2) to block Fc receptors, and then stained with the following anti-
bodies: CD8α (53-6.7), B220 (RA3-6B2), Ly6C (AL-21), Ly6G (1A8), CD45.2
(104), CD11c (HL3), CD11b (M1/70), CD44 (IM7), Siglec-F (E50-2440), and NK
1.1 (PK136) (BD Biosciences); CD3e (145-2C11), CD4 (GK1.5), CD11c (N418),
CD317 (BST-2, eBio927), CD62L (MEL-14), FceRI (MAR-1), Sca-1 (D7), c-kit
(2B8), and IL-7R (CD127, A7R34) (eBioscience); MHCII (M5/114.15.2), and ST2
(DIH9) (BioLegend). Leukocytes were gated on the basis of forward and side-
scatter properties, and live cells were gated on the basis of DAPI (Invitrogen)
or propidium iodide (PI) exclusion. For M2 macrophage staining, single cells
isolated from vagina were pretreated with anti-CD16/32 antibody (2.4G2),
and surface-stained with F4/80 (BM8) (eBioscience), CD11b (M1/70) (BD
Biosciences), CD115 (AFS98), CD11c (N418), and CD45.2 (104) (BioLegend).
Then, cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD
Biosciences), and intracellular stained with CD206 (C068C2) (BioLegend).
Leukocytes from the iliac lymph nodes and vagina of infected mice were
cultured in the presence of 50 ng/mL phorbol myristate acetate (PMA)
(Sigma-Aldrich) and 1 μg/mL ionomycin (Sigma-Aldrich) for 5 h, and 2 μM
GolgiStop (BD Biosciences) was added for the final 2 h. Cells were surface-
stained with CD3e (145-2C11), and CD4 (GK1.5) (eBioscience), CD8α (53-6.7),
and CD44 (IM7) (BD Biosciences), and then fixed and permeabilized using a
Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s in-
structions. For intracellular cytokine staining, APC-labeled anti-mouse IFN-γ
antibody (XMG1.2; BD Biosciences) or PE-labeled anti-mouse IL-4 antibody
(11B11; BD Biosciences) was used. Live cells were gated using Ghost Dye
(TONBO biosciences) for intracellular staining. All samples were acquired on
an LSR Fortessa cell analyzer (BD Biosciences). All data were analyzed using
FlowJo (Treestar).
Intravaginal Papain Injection. Mice were injected subcutaneously with
medroxyprogesterone acetate (Tokyo Chemical Industry) at 2 mg per mouse
in 100 μL at 7 d before injection, swabbed with calcium alginate, and in-
oculated intravaginally with 200 μg active papain or heat-inactivated
(95 °C, 45 min) papain (Calbiochem) for 3 consecutive days after anesthe-
sia with intraperitoneal ketamine (100 mg/kg) and xylazine (5.83 mg/kg)
injection.
Statistical Analysis. Data are expressed as the mean ± SEM. Differences be-
tween groups on individual time points were analyzed using the unpaired,
two tailed Student’s t test. Disease scores were analyzed by two-way ANOVA
test. Differences in survival were evaluated using the Log-Rank test. Statis-
tical analysis was performed using GraphPad Prism software (GraphPad).
Differences were considered statistically significant when P < 0.05, and are
indicated as follows: *P < 0.05; **P < 0.01; and ***P < 0.001.
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